ENTREPRISE COMMUNE POUR LA MISE EN OEUVRE DE LA MEDECINE INNOVATIVE

Avenue de la Toison d'Or 56-60
1060
BRUXELLES  ()
www.imi.europa.eu
INFODESK@imi.europa.eu
Pierre Meulien is Executive Director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the programme, which is working to improve and accelerate the entire medicines development process by facilitating collaboration between the key players involved in health research, including universities, pharmaceutical and other companies, patient organisations, and medicines regulators. Dr Meulien joined IMI in September 2015. From 2010 to 2015, Dr Meulien was President and CEO of Genome Canada, where he raised significant funds for the organisation and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that from 2007 to 2010, he was Chief Scientific Officer for Genome British Columbia. From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked medical schools and teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. Dr Meulien also worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur). He has a PhD in molecular biology from the University of Edinburgh and carried out a post-doctoral fellowship at the Institut Pasteur in Paris. Dr Meulien has Irish nationality.
Pierre Meulien is Executive Director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the programme, which is working to improve and accelerate the entire medicines development process by facilitating collaboration between the key players involved in health research, including universities, pharmaceutical and other companies, patient organisations, and medicines regulators. Dr Meulien joined IMI in September 2015. From 2010 to 2015, Dr Meulien was President and CEO of Genome Canada, where he raised significant funds for the organisation and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that from 2007 to 2010, he was Chief Scientific Officer for Genome British Columbia. From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked medical schools and teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. Dr Meulien also worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur). He has a PhD in molecular biology from the University of Edinburgh and carried out a post-doctoral fellowship at the Institut Pasteur in Paris. Dr Meulien has Irish nationality.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.





     

© Worldinz 2015